参考文献
[1] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019,24(1):24‑56. DOI: 10.3969/j.issn.1007‑5410.2019.01.002
[2] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018,39(33):3021‑3104. DOI: 10.1093/eurheartj/ehy339.
[3] Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: results from the China hypertension survey, 2012‑2015[J]. Circulation, 2018,137(22):2344‑2356. DOI: 10.1161/CIRCULATIONAHA.117.032380.
[4] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Hypertension, 2018,71(6):e13‑e115. DOI: 10.1161/HYP.0000000000000065.
[5] Umemura S, Arima H, Arima S, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019)[J]. Hypertens Res, 2019,42(9):1235‑1481. DOI: 10.1038/s41440‑019‑0284‑9.
[6] World Health Organization. Guideline for the pharmacological treatment of hypertension in adults[M/OL]. Geneva: World Health Organization,2021[2022‑06‑28]. https://www.who.int/publications/i/item/9789240033986.
[7] 刘力生, 张维忠, 郝建生, 等. 非洛地平缓释片在高血压治疗中的达标率和安全性研究[J]. 中华心血管病杂志, 2004, 32(4):291‑294. DOI: 10.3760/j:issn:0253‑3758.2004.04.002.
[8] Lu Y, Van Zandt M, Liu Y, et al. Analysis of dual combination therapies used in treatment of hypertension in a multinational cohort[J]. JAMA Netw Open, 2022,5(3):e223877. DOI: 10.1001/jamanetworkopen.2022.3877.
[9] Sica DA. Rationale for fixed‑dose combinations in the treatment of hypertension: the cycle repeats[J]. Drugs, 2002,62(3):443‑462. DOI: 10.2165/00003495‑200262030‑00003.
[10] Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood‑pressure lowering and low‑dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group[J]. Lancet, 1998,351(9118):1755‑1762. DOI: 10.1016/s0140‑6736(98)04311‑6.
[11] Devi P, Xavier D, Sigamani A, et al. Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS‑‑a randomized controlled trial[J]. Blood Press Suppl, 2011,2:5‑12. DOI: 10.3109/08037051.2011.617040.
[12] Pareek A, Salkar H, Mulay P, et al. A randomized, comparative, multicentric evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertensive patients[J]. Am J Ther, 2010,17(1):46‑52. DOI: 10.1097/MJT.0b013e3181a9db74.
[13] Foch C, Feifel J, Gottwald‑Hostalek U. An anchored simulated treatment comparison of uptitration of amlodipine compared with a low‑dose combination treatment with amlodipine 5 mg/bisoprolol 5 mg for patients with hypertension suboptimally controlled by amlodipine 5 mg monotherapy[J]. Curr Med Res Opin, 2022,38(4):587‑593. DOI: 10.1080/03007995.2022.2030112.
[14] Guo Q, Lin J, Peng F, et al. Cardiovascular outcomes of initial beta‑blocker+calcium channel blocker therapy vs other dual therapies in Chinese patients with newly diagnosed hypertension: a real‑world study[J]. J Hypertens, 2022,40(e‑Suppl 1):e302. DOI: 10.1097/01.hjh.0000838668.20434.ca.
[15] Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk[J]. J Hypertens, 2011,29(3):610‑618. DOI: 10.1097/HJH.0b013e328342ca97.
[16] Coca A, Agabiti‑Rosei E, Cifkova R, et al. The polypill in cardiovascular prevention: evidence, limitations and perspective ‑position paper of the European Society of Hypertension[J]. J Hypertens, 2017,35(8):1546‑1553. DOI: 10.1097/HJH.0000000000001390.
[17] Xie L, Frech‑Tamas F, Marrett E, et al. A medication adherence and persistence comparison of hypertensive patients treated with single‑, double‑ and triple‑pill combination therapy[J]. Curr Med Res Opin, 2014,30(12):2415‑2422. DOI: 10.1185/03007995.2014.964853.
[18] Parati G, Kjeldsen S, Coca A, et al. Adherence to single‑pill versus free‑equivalent combination therapy in hypertension: a systematic review and meta‑analysis[J]. Hypertension, 2021,77(2):692‑705. DOI: 10.1161/HYPERTENSIONAHA.120.15781.
[19] Tsioufis K, Kreutz R, Sykara G, et al. Impact of single‑pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature[J]. J Hypertens, 2020,38(6):1016‑1028. DOI: 10.1097/HJH.0000000000002381.
[20] Wilke T, Weisser B, Predel HG, et al. Effects of single pill combinations compared to identical multi pill therapy on outcomes in hypertension, dyslipidemia and secondary cardiovascular prevention: the START‑Study[J]. Integr Blood Press Control, 2022,15:11‑21. DOI: 10.2147/IBPC.S336324.
[21] Borghi C, Wang J, Rodionov AV, et al. Projecting the long‑term benefits of single pill combination therapy for patients with hypertension in five countries[J]. Int J Cardiol Cardiovasc Risk Prev, 2021,10:200102. DOI: 10.1016/j.ijcrp.2021.200102.
[22] Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year[J]. Hypertension, 2012,59(6):1124‑1131. DOI: 10.1161/HYPERTENSIONAHA. 112.194167.
[23] 高血压心率管理多学科共识组. 中国高血压患者心率管理多学科专家共识(2021年版)[J]. 中国医学前沿杂志(电子版), 2021,13(4):38‑48. DOI: 10.12037/YXQY.2021.04-07.
[24] Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020,41(3):407‑477. DOI: 10.1093/eurheartj/ehz425.
[25] Belsey J, Savelieva I, Mugelli A, et al. Relative efficacy of antianginal drugs used as add‑on therapy in patients with stable angina: a systematic review and meta‑analysis[J]. Eur J Prev Cardiol, 2015,22(7):837‑848. DOI: 10.1177/2047487314533217.
[26] 中国医疗保健国际交流促进会心血管病学分会. 高血压合并冠心病患者血压管理中国专家共识[J]. 中华医学杂志, 2022,102(10):717‑728. DOI: 10.3760/cma.j.cn112137‑20211208‑02738.
[27] Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy[J]. Cochrane Database Syst Rev, 2018,10:CD002252. DOI: 10.1002/14651858.CD002252.pub4.
[28] Frishman WH, Alwarshetty M. Beta‑adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines[J]. Clin Pharmacokinet, 2002,41(7):505‑516. DOI: 10.2165/00003088‑200241070‑00004.
[29] Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol[J]. Lancet, 2002,359(9311):995‑1003. DOI: 10.1016/S0140‑6736(02)08089‑3.
[30] Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‑Scandinavian Cardiac Outcomes Trial‑Blood Pressure Lowering Arm (ASCOT‑BPLA): a multicentre randomised controlled trial[J]. Lancet, 2005,366(9489):895‑906. DOI: 10.1016/S0140‑6736(05)67185‑1.
[31] Zhang Y, Sun N, Jiang X, et al. Comparative efficacy of β‑blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta‑analysis[J]. J Am Soc Hypertens, 2017,11(7):394‑401. DOI: 10.1016/j.jash.2017.05.001.
[32] Neil‑Dwyer G, Bartlett J, McAinsh J, et al. Beta‑adrenoceptor blockers and the blood‑brian barrier[J]. Br J Clin Pharmacol, 1981,11(6):549‑553. DOI: 10.1111/j.1365‑2125.1981.tb01169.x.
[33] Staessen JA, Fagard R, Thijs L, et al. Randomised double‑blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst‑Eur) trial investigators[J]. Lancet, 1997,350(9080):757‑764. DOI: 10.1016/s0140‑6736(97)05381‑6.
[34] Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in China (Syst‑China) collaborative group[J]. J Hypertens, 1998,16(12 Pt 1):1823‑1829. DOI: 10.1097/00004872‑199816120‑00016.
[35] Bakheit AH, Ali A, Alshahrani AD, et al. Profiles of drug substances, excipients, and related methodology[M/OL]. Amsterdam:Elsevier,2021,46:2‑316[2022‑08‑02]. https://www.sciencedirect.com/bookseries/profiles‑of‑drug‑substances‑ excipients‑and‑related‑methodology/vol/46/suppl/C.
[36] McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure[J]. Drugs, 2002,62(18):2677‑2696. DOI: 10.2165/00003495‑200262180‑00017.
[37] Payton CD, Fox JG, Pauleau NF, et al. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance[J]. Eur Heart J, 1987,8 Suppl M:15‑22. DOI: 10.1093/eurheartj/8.suppl_m.15.
[38] Jankovic SM. Pharmacokinetics of selective β1‑adrenergic blocking agents: prescribing implications[J]. Expert Opin Drug Metab Toxicol, 2014,10(9):1221‑1229. DOI: 10.1517/17425255.2014.937702.
[39] CIBIS‑II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS‑II): a randomised trial[J]. Lancet, 1999,2, 353(9146):9‑13.
[40] Abernethy DR. Amlodipine: pharmacokinetic profile of a low‑clearance calcium antagonist[J]. J Cardiovasc Pharmacol, 1991,17 Suppl 1:S4‑7.
[41] 苯磺酸氨氯地平临床应用中国专家组. 苯磺酸氨氯地平临床应用中国专家建议[J]. 中华内科杂志, 2009,48(11):974‑979. DOI: 10.3760/cma.j.issn.0578‑1426.2009.11.029.
[42] ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid‑lowering treatment to prevent heart attack trial. Major outcomes in high‑risk hypertensive patients randomized to angiotensin‑converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid‑lowering treatment to prevent heart attack trial (ALLHAT)[J]. JAMA, 2002,288(23):2981‑2997. DOI: 10.1001/jama.288.23.2981.
[43] Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial[J]. JAMA, 2002,288(19):2421‑2431. DOI: 10.1001/jama.288.19.2421.
[44] Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial[J]. Lancet, 2004,363(9426):2022‑2031. DOI: 10.1016/S0140‑6736(04)16451‑9.
[45] Lee SA, Choi HM, Park HJ, et al. Amlodipine and cardiovascular outcomes in hypertensive patients: meta‑analysis comparing amlodipine‑based versus other antihypertensive therapy[J]. Korean J Intern Med, 2014,29(3):315‑324. DOI: 10.3904/kjim.2014.29.3.315.
[46] Gottwald‑Hostalek U, Li L, Montenegro P. Bisoprolol/amlodipine combination therapy improves blood pressure control in patients with essential hypertension following monotherapy failure[J]. Curr Med Res Opin, 2016,32(10):1735‑1743. DOI: 10.1080/03007995.2016.1205573.
[47] Bogomaz A, Kotovoskaya Y, Kobalava Z. Combination with amlodipine eliminates adverse effects of a beta‑blocker on aortic pulse pressure augmentation[J]. J Hypertens, 2015,33(e‑Supppl 1):e326.
[48] Hostalek U, Czarnecka D, Koch EM. Treatment of hypertensive patients with a fixed‑dose combination of bisoprolol and amlodipine: results of a cohort study with more than 10,000 patients[J]. Cardiol Ther, 2015,4(2):179‑190. DOI: 10.1007/s40119‑015‑0045‑z.
[49] Hostalek U, Koch EMW. Treatment of hypertension with a fixed‑dose combination of bisoprolol and amlodipine in daily practice: results of a multinational non‑investigational study[J]. Cardiovasc Disord Med, 2016,1(3):1‑5. DOI: 10.15761/CDM.1000118.
[50] Chesnikova AI, Safronenko VA, Kolomatskaia OE. Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease[J]. Kardiologiia, 2014,54(9):17‑23. DOI: 10.18565/cardio.2014.9.17-23.